Abstract
Abstract
Purpose
Information about the cost-effectiveness of a certain treatment is relevant for decision-making and healthcare providers. This study compares the cost-effectiveness of the novel Woven Endobridge (WEB) for intracranial aneurysm treatment with conventional coiling and stent-assisted coiling (SAC) from the perspective of the German Statutory Health Insurance.
Methods
A patient-level simulation was constructed to simulate 55-year-old patients with an unruptured middle cerebral artery aneurysm (size: 3–11 mm) considering WEB treatment, coiling or SAC in terms of morbidity, angiographic outcome, retreatment, procedural and rehabilitation costs and rupture rates. Incremental cost-effectiveness ratios (ICERs) were calculated as costs per quality-adjusted life years (QALYs) and costs per year with neurologic morbidity avoided. Uncertainty was explored with deterministic and probabilistic sensitivity analyses. The majority of data were obtained from prospective multi-center studies and meta-analyses of non-randomized studies.
Results
In the base case, lifetime QALYs were 13.24 for the WEB, 12.92 for SAC and 12.68 for coiling. Lifetime costs were 20,440 € for the WEB, 23,167 € for SAC, and 8200 € for coiling. Compared to coiling, the ICER for the WEB was 21,826 €/QALY, while SAC was absolutely dominated by WEB. Probabilistic sensitivity analysis revealed that at a willingness-to-pay of ≥ 30,000 €/QALY, WEB was the preferred treatment. Deterministic sampling showed that the discount rate, material costs and retreatment rates had the largest impact on the ICERs.
Conclusion
The novel WEB showed at least comparable cost-effectiveness to SAC for treatment of broad-based unruptured aneurysms. Considering all three modalities, coiling had the least costs; however this modality is often not appropriate for the treatment of wide-necked aneurysms.
Funder
Universitätsklinikum Köln
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Radiology, Nuclear Medicine and imaging
Reference44 articles.
1. Arzneimittelinformationen für Deutschland Stand: Januar 2022 (Arzneimittelinformationen), 1. Februar 2022 (Preise). https://www.rote-liste.de/. Accessed 17 February 2022
2. Ariyada K, Ohida T, Shibahashi K, Hoda H, Hanakawa K, Murao M. Long-term functional outcomes for world federation of neurosurgical societies grade V aneurysmal subarachnoid hemorrhage after active treatment. Neurol Med Chir. 2020;60:390–6.
3. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford University Press; 2006.
4. Busse R, Blümel M, Knieps F, Bärnighausen T. Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition. Lancet. 2017;390:882–97.
5. Consortium YHE. Cost-effectiveness threshold. 2016. https://yhec.co.uk/glossary/cost-effectiveness-threshold/. Accessed 2 June 2022.